Danish multinational pharmaceutical company Novo Nordisk’s end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without.
HQ Team October 15, 2024: A recent study presented at the United European Gastroenterology Week congress in Vienna unveiled a procedure that could.
HQ Team August 22, 2024: A new study based on data from the World Health Organization’s records on adverse drug reactions found that.
HQ Team July 31, 2024: A new research published in the Annals of Internal Medicine reveals that semaglutide is effective in helping people quit.
The European Medicines Agency has backed Novo Nordisk’s Wegovy to expand the weight-loss drug’s application to lower heart risks and strokes in non-diabetic.
The UK’s Medicines and Healthcare products Regulatory Agency has approved Novo Nordisk’s weight-loss drug to cut the risk of obesity and adults suffering.
Research finds a sharp increase in use of weightloss drugs such as Ozempic and Wegovy among teens and young adults
HQ Team March 11, 2024: Danish drugmaker Novo Nordisk’s oral medicine, amycretin, for obesity can cause up to 13% weight loss, the company.
HQ Team March 6, 2024: Novo Nordisk’s diabetes drug Ozempic delayed the progression of kidney disease and cardiovascular and kidney death in 24%.
